Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1

• Main Authors: NAGAYAMA, SATOSHI, INOUE, TADASHI, SHISHIDO, YUJI, KAWASHIMA, TADASHI
• Format: Patent
• Language: Spanish
• Published: 14.06.2012
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Un compuesto de la fórmula (I) : en la que A=B=D representa NR10-C (O) -NR9, S-C (O) -NR9, NR9-C (O) -S, NR9-C (O) O, CR10-C (O) -NR9, O-C (O) -NR9, NR10-C (O) -CR, NR10-NR9-C (O), C (O) -NR9-NR10, NR10-N=CR9, N=N-CR9, NR10-CR9=N, N=CR9-NR10, NR10-N=N, N=N-NR10, S-CR9=N o N=CR9-S;X1 representa CR1; X2 y X3 representa cada uno independientemente CR8; R1, R6, R8, R9 y R10 representa cada uno independientemente hidrógeno, halógeno, hidroxilo, alquilo (C1-C6), alcoxilo (C1-C8), hidroxialcoxilo (C1-C6), alcoxi (C1-C6) -alquilo (C1-C6), alcoxi (C1-C6) -alcoxilo (C1-C6), haloalquilo (C1-C6), alquiltio (C1-C6), alquilsulfinilo (C1-C6) o alquilsulfonilo (C1-C6); R2, R3, R4, y R5 representa cada uno independientemente hidrógeno, alquilo (C1-C6), halógeno, haloalquilo (C1-C6) o hidroxialquilo (C1-C6); y R7 representa halógeno, alquilo (C1-C6), haloalquilo (C1-C6), alcoxilo (C1-C6), hidroxialcoxilo (C1-C6), alcoxi (C1-C6) -alquilo (C1-C8), alcoxi (C1-C6) -alcoxilo (C1-C6), [alquilo (C1-C6) ]NH- o [alquilo (C1-C6) ]2N-; o una de sus sales farmacéuticamente aceptables, con la condición de que: (i) cuando A=B=D representa NR10-N=N o N=N-NR10, entonces R2 representa alquilo (C1-C6), halógeno, haloalquilo (C1-C6) o hidroxialquilo (C1-C6); o (ii) cuando A=B=D representa NR10-N=N o N=N-NR10 y R2 representa alquilo (C1-C6), entonces R7 representa halógeno, alquilo (C1-C6), alcoxilo (C1-C6), hidroxialcoxilo (C1-C6), alcoxi (C1-C6) -alquilo (C1-C6), 20 alcoxi (C1-C6) -alcoxilo (C1-C6), [alquilo (C1-C6) ]NH- o [alquilo (C1-C6) ]2N-. Compounds of the general formula (I): pharmaceutical compositions comprising a compound of general formula (I); and methods of treating disease conditions caused by overactivation of the VR1 receptor by administering a compound of general formula (I) to a subject.